Top Page
China Isotope & Radiation Corp.
(1763)
China Isotope & Radiation Corp. (1763) vs. iShares MSCI Hong Kong ETF (EWH)
China Isotope & Radiation Corp. Business Overview & Revenue Model
China Isotope & Radiation Corp. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.62B | 7.57B | 6.63B | 6.15B | 5.14B | 4.27B |
| Gross Profit | 3.68B | 3.68B | 3.48B | 3.51B | 3.24B | 2.62B |
| EBITDA | 1.34B | 1.28B | 1.22B | 1.05B | 901.43M | 717.43M |
| Net Income | 424.14M | 406.64M | 370.97M | 392.27M | 335.75M | 213.58M |
Balance Sheet | ||||||
| Total Assets | 15.65B | 14.77B | 13.19B | 11.69B | 10.47B | 9.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.69B | 2.63B | 2.94B | 2.93B | 2.79B | 2.59B |
| Total Debt | 3.02B | 2.57B | 1.70B | 903.86M | 856.63M | 749.64M |
| Total Liabilities | 7.69B | 7.02B | 6.05B | 5.13B | 4.44B | 3.68B |
| Stockholders Equity | 5.08B | 5.01B | 4.69B | 4.47B | 4.18B | 3.89B |
Cash Flow | ||||||
| Free Cash Flow | -766.49M | 142.48M | -812.66M | 328.66M | 366.59M | -118.01M |
| Operating Cash Flow | 14.07M | 142.48M | 84.96M | 862.66M | 794.31M | 291.91M |
| Investing Cash Flow | -347.00M | -564.81M | -429.88M | -506.62M | -907.36M | -423.90M |
| Financing Cash Flow | 608.94M | 499.70M | 484.37M | -291.50M | -97.44M | -156.25M |
China Isotope & Radiation Corp. Technical Analysis
China Isotope & Radiation Corp. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$6.56B | 14.31 | 8.59% | 2.76% | 13.59% | 6.31% | |
69 Neutral | HK$6.42B | 20.04 | 11.24% | 1.26% | 25.18% | 55.79% | |
58 Neutral | HK$7.88B | 44.63 | 4.99% | 0.48% | 35.01% | 483.73% | |
55 Neutral | HK$9.03B | 20.89 | 8.69% | 1.88% | 14.56% | 61.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$6.30B | 450.00 | 0.22% | ― | -4.38% | ― |
China Isotope & Radiation Corp. Corporate Events
China Isotope & Radiation Corporation (CIRC) has entered into a strategic cooperation agreement with CNNC Capital Holdings Limited to enhance the integration of the nuclear technology application industry chain. This collaboration aims to overcome technological bottlenecks and foster new productive forces through mergers, acquisitions, and equity investments, thereby empowering CIRC with financial capital for high-quality development.
China Isotope & Radiation Corporation has announced its first export of self-produced irradiation equipment to the Latin American market, specifically to a Peruvian client for an Agricultural Gamma Irradiation Station Project. This project, aligned with the Belt and Road Initiative and the IAEA’s ‘Atoms for Food’ initiative, aims to improve the sterilization and shelf life of agricultural products, enhancing their market competitiveness. It also represents a step forward in China-Peru nuclear technology cooperation, potentially opening new global opportunities for China’s nuclear technology sector.
China Isotope & Radiation Corporation has signed an agreement with Brazil’s National Nuclear Energy Commission to supply cobalt-60 radioactive sources for irradiation purposes. This marks CIRC’s first export of self-produced cobalt-60 to the Latin American market, enhancing Brazil’s irradiation capacity and promoting the benefits of irradiation technology in various fields.
China Isotope & Radiation Corporation announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has been recognized as a National-Level Manufacturing Enterprise and awarded the ‘Single-Item Champion in the Pharmaceutical Industry’ for its Urea [13C/14C] Breath Test Kits. This accolade underscores CIRC’s leading position in the breath diagnostic sector and its commitment to innovation and expanding its product offerings to enhance national health defenses.
CIRC has announced a significant technological breakthrough in the production of carbon isotope products, specifically high-abundance 13CO gas, which is crucial for urea breath tests detecting Helicobacter pylori infections. This advancement positions China among the few countries capable of producing these materials, reducing reliance on imports and enhancing the nation’s research and production capabilities in stable isotope technology. Additionally, CIRC has started phase II construction of its stable isotope base project, which will ensure a stable supply of these materials, contributing to public health improvements and supporting the Healthy China Initiative.
China Isotope & Radiation Corporation has been recognized for its exemplary ESG practices, receiving the Outstanding China ESG Practice and ESG Pioneers Index (Top 100) awards at the ESG China Innovation Annual Conference 2025. The company’s focus on technological innovation and sustainable development has led to significant advancements in nuclear technology applications, contributing to economic, environmental, and social benefits while supporting China’s health initiatives.
China Isotope & Radiation Corporation announced the successful results of its Extraordinary General Meeting (EGM) held on October 17, 2025. Key resolutions approved included the appointment of a domestic auditor for 2025 and the declaration of an interim dividend of RMB0.0807 per share for the first half of 2025. This decision reflects the company’s commitment to shareholder returns and may enhance its market positioning by demonstrating financial stability and operational transparency.
China Isotope & Radiation Corporation has announced an updated interim dividend for the six months ending June 30, 2025, with a declared dividend of RMB 0.0807 per share. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09528, with the payment date set for December 31, 2025. The announcement includes details on withholding tax rates applicable to non-resident shareholders, which vary based on their country of residence and existing tax treaties with China. This update reflects the company’s commitment to shareholder returns and provides clarity on the financial implications for international investors.
China Isotope & Radiation Corporation’s subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has submitted an IND application for its innovative BNCT boron drug, ‘Borofalan (10B) for Injection,’ which has been accepted by the National Medical Products Administration. This development marks a significant breakthrough in China’s BNCT technology, enhancing precision tumor treatment and contributing to global oncology advancements.
China Isotope & Radiation Corporation has announced the launch of a new isotope separation technology called the ‘Adsorption Trapper’ by its subsidiary, Chengdu Gaotong Isotope Co., Ltd. This innovative technology utilizes fourth-generation MOF materials to enhance nuclear medicine and nuclear fusion development, offering high purity and efficiency at a lower cost. The advancement is expected to significantly impact the national economy by supporting key areas such as nuclear medicine and biomedical research, while also reducing China’s reliance on imported high-end isotopes.
China Isotope & Radiation Corporation (CIRC) has signed a Memorandum of Understanding with Brazil’s National Commission for Nuclear Energy to establish a long-term cooperation mechanism. This partnership aims to enhance isotope product supply, quality management, and information exchange, supporting Brazil’s nuclear technology and radiopharmaceutical industries. The agreement is expected to help CIRC expand its international cooperation, promote its technologies, and contribute to the peaceful uses of nuclear technology.
China Isotope & Radiation Corporation has announced an interim cash dividend of RMB 0.0807 per share for the six months ending June 30, 2025. The announcement includes details about the ex-dividend date, book closure period, and payment date, which are crucial for shareholders to determine their entitlement. This dividend declaration reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor sentiment positively.
China Isotope & Radiation Corporation has announced the postponement of its Extraordinary General Meeting (EGM) originally scheduled for September 17, 2025, now rescheduled to October 17, 2025, due to work arrangements and coordination needs. This delay also affects the payment schedule for the interim dividend for the first half of 2025, which will now be paid by December 31, 2025, instead of the originally planned date in November. These changes may impact shareholder planning and expectations regarding dividend payments.
China Isotope & Radiation Corporation has announced the approval and upcoming launch of its novel Su π one 13C breath analyzer, which has received a Class II medical device registration certificate. This device represents a significant advancement in Helicobacter pylori breath testing technology, offering more reliable and efficient diagnostics. The analyzer reduces testing time from 2 minutes to 30 seconds, enhancing user experience and allowing for broader application in large-scale screening scenarios. This development supports early screening and diagnosis systems for gastric cancer in China, potentially improving healthcare resource utilization.